Intra-articular therapy with tumor necrosis factor-α antagonists: an update

Intra-articular therapy with tumor necrosis factor-α antagonists: an update

The aim of the study was to review from the present literature the intra-articular (IA) use of the TNF-blocking drugs. A total of 28 papers about this topic were found through a search in PubMed; the first publication’s date was July 2003. These studies include a total of 214 patients affected by 12...

Full description

Bibliographic Details
Main Authors: S. Bello, C. Bonali, L. Serafino, C. Rotondo, N. Terlizzi, G. Lapadula
Format: Article
Language:English
Published: PAGEPress Publications 2014-03-01
Series:Reumatismo
Subjects:
intra-articular therapy
sieronegative spondyloarthritis
anti-TNF agents
refractory monoarthritis.
Online Access:http://www.reumatismo.org/index.php/reuma/article/view/721
id doaj-d44379ecfd9448cfa7c7c4636ba051b6
record_format Article
spelling doaj-d44379ecfd9448cfa7c7c4636ba051b62020-11-24T23:16:19ZengPAGEPress PublicationsReumatismo0048-74492240-26832014-03-0165625726310.4081/reumatismo.2013.721625Intra-articular therapy with tumor necrosis factor-α antagonists: an updateS. Bello0C. Bonali1L. Serafino2C. Rotondo3N. Terlizzi4G. Lapadula5Rheumatology Unit, Policlinico Hospital, University of BariRheumatology Unit, Policlinico Hospital, University of BariRheumatology Unit, Policlinico Hospital, University of BariRheumatology Unit, Policlinico Hospital, University of BariRheumatology Unit, Policlinico Hospital, University of BariRheumatology Unit, Policlinico Hospital, University of BariThe aim of the study was to review from the present literature the intra-articular (IA) use of the TNF-blocking drugs. A total of 28 papers about this topic were found through a search in PubMed; the first publication’s date was July 2003. These studies include a total of 214 patients affected by 12 different joint diseases that reported a total of 1046 intra-articular therapies carried out in 10 different joint sites. Infliximab and etanercept were the most widely used medications. The safety of this treatment clearly emerges from our analysis, while more difficult was the evaluation of its efficacy. Nevertheless we deduced an ideal patient profile that may better respond to the IA anti-TNF treatment.http://www.reumatismo.org/index.php/reuma/article/view/721intra-articular therapysieronegative spondyloarthritisanti-TNF agentsrefractory monoarthritis.
collection DOAJ
language English
format Article
sources DOAJ
author S. Bello
C. Bonali
L. Serafino
C. Rotondo
N. Terlizzi
G. Lapadula
spellingShingle S. Bello
C. Bonali
L. Serafino
C. Rotondo
N. Terlizzi
G. Lapadula
Intra-articular therapy with tumor necrosis factor-α antagonists: an update
Reumatismo
intra-articular therapy
sieronegative spondyloarthritis
anti-TNF agents
refractory monoarthritis.
author_facet S. Bello
C. Bonali
L. Serafino
C. Rotondo
N. Terlizzi
G. Lapadula
author_sort S. Bello
title Intra-articular therapy with tumor necrosis factor-α antagonists: an update
title_short Intra-articular therapy with tumor necrosis factor-α antagonists: an update
title_full Intra-articular therapy with tumor necrosis factor-α antagonists: an update
title_fullStr Intra-articular therapy with tumor necrosis factor-α antagonists: an update
title_full_unstemmed Intra-articular therapy with tumor necrosis factor-α antagonists: an update
title_sort intra-articular therapy with tumor necrosis factor-α antagonists: an update
publisher PAGEPress Publications
series Reumatismo
issn 0048-7449
2240-2683
publishDate 2014-03-01
description The aim of the study was to review from the present literature the intra-articular (IA) use of the TNF-blocking drugs. A total of 28 papers about this topic were found through a search in PubMed; the first publication’s date was July 2003. These studies include a total of 214 patients affected by 12 different joint diseases that reported a total of 1046 intra-articular therapies carried out in 10 different joint sites. Infliximab and etanercept were the most widely used medications. The safety of this treatment clearly emerges from our analysis, while more difficult was the evaluation of its efficacy. Nevertheless we deduced an ideal patient profile that may better respond to the IA anti-TNF treatment.
topic intra-articular therapy
sieronegative spondyloarthritis
anti-TNF agents
refractory monoarthritis.
url http://www.reumatismo.org/index.php/reuma/article/view/721
work_keys_str_mv AT sbello intraarticulartherapywithtumornecrosisfactoraantagonistsanupdate
AT cbonali intraarticulartherapywithtumornecrosisfactoraantagonistsanupdate
AT lserafino intraarticulartherapywithtumornecrosisfactoraantagonistsanupdate
AT crotondo intraarticulartherapywithtumornecrosisfactoraantagonistsanupdate
AT nterlizzi intraarticulartherapywithtumornecrosisfactoraantagonistsanupdate
AT glapadula intraarticulartherapywithtumornecrosisfactoraantagonistsanupdate
_version_ 1725587559270055936

Similar Items